Table 1 Baseline characteristics of included studies [8, 9, 12,13,14,15]
From: Systematic review and meta-analysis of the clinical features of MGRS
Author(year) | Country | Study design | Case | Control | Prevalence (MG patients who underwent renal biopsy) | NOS |
|---|---|---|---|---|---|---|
Yong et al.(2022) | China | Case-control study | 261 | 426 | 38% | 7 |
Klomjit et al. (2020) | America | Case-control study | 64 | 96 | 40% | 7 |
Tang et al.(2021) | China | Case-control study | 42 | 19 | / | 6 |
Nie et al.(2021) | China | Case-control study | 43 | 42 | 51% | 6 |
Yu et al.(2020) | China | Case-control study | 187 | / | / | 6 |
Gozzetti et al.(2022) | Europe and America | Case-control study | 280 | / | / | 7 |